In polycystic liver diseases (PCLDs), increased cholangiocyte proliferation and fluid secretion are key features and cholangiocyte adenosine 3=,5=-cyclic monophosphate (cAMP) is an important regulator of these processes. Thus, we assessed cAMP levels and evaluated octreotide (an analogue of somatostatin known to inhibit cAMP) in hepatic cyst growth using an in vitro model of cystogenesis and an in vivo animal model of autosomal recessive polycystic kidney disease (ARPKD), one of the PCLDs. Methods: Expression of somatostatin receptors (SSTRs) was assessed by reverse-transcription polymerase chain reaction and confocal microscopy in cholangiocytes from normal and polycystic kidney (PCK) rats, the ARPKD model of autosomal recessive polycystic kidney disease. Effects of octreotide on cAMP levels and cyst expansion were studied in vitro using PCK bile ducts grown in 3-dimensional culture. The effects of octreotide on hepatic and renal cystogenesis were investigated in PCK rats in vivo. Results: In cholangiocytes and serum of PCK rats, cAMP concentrations were ϳ2 times higher than in normal rats. SSTR subtypes that bind octreotide (ie, SSTR2, SSTR3, and SSTR5) were expressed in both normal and PCK cholangiocytes. In vitro, octreotide inhibited cAMP levels by 35% and reduced cyst growth by 44%. In vivo, octreotide lowered cAMP content in cholangiocytes and serum by 32%-39% and inhibited hepatic disease progression, leading to 22%-60% reductions in liver weight, cyst volume, hepatic fibrosis, and mitotic indices. Similar effects were observed in kidneys of PCK rats. Conclusions: This preclinical study provides a strong rationale for assessing the potential value of octreotide in the treatment of PCLDs.
T he polycystic liver diseases (PCLDs) are a group of genetically and clinically heterogeneous disorders that occur alone (autosomal dominant PCLD) or in association with polycystic kidney disease (autosomal recessive polycystic kidney disease [ARPKD] or autosomal dominant polycystic kidney disease [ADPKD]). [1] [2] [3] In ADPLD, mutations in 2 genes, PRKCSH (which encodes protein, hepatocystin) and sec63, lead to formation of liver cysts. 4 -7 ADPKD is linked to a mutation in either PKD1 or PKD2, genes that encode the proteins polycystin 1 and polycystin 2, respectively. Liver involvement is the most frequent extrarenal manifestation in ADPKD; approximately 80% of patients with ADPKD develop hepatic cysts by the age of 60 years. 1, 8, 9 In ARPKD, genetic linkage studies indicate mutations in a single gene, PKHD1, that encodes the protein fibrocystin/polyductin. 10, 11 Liver involvement in ARPKD is associated with congenital hepatic fibrosis, bile duct dilation, and hepatic cystogenesis. 1, 3, 12, 13 Liver symptoms and complications in all the PCLDs include abdominal distention or discomfort, back pain, cyst infection, fullness, hemorrhage, and rupture, and, in PCLD and ARPKD, portal hypertension and jaundice. To date, no curative or preventive therapy for PCLD exists. For symptomatic relief, interventional or surgical options include cyst fenestration, aspiration of cyst fluid, liver resection, and isolated liver or combined liver-kidney transplantation. 1, 3 In all the PCLDs, well-described genetic defects 1,2,4-6,13,14 initiate formation of hepatic cysts, which arise from cholangiocytes. Cysts further expand due to disturbances in at least 3 processes: (1) cell proliferation, apoptosis, and differentiation; (2) cell-matrix interactions; and (3) fluid secretion. Different factors, individually or in combination, could impact these processes and promote cyst growth. 1, 3, 15 One of these potential factors is adenosine 3=,5=-cyclic monophosphate (cAMP), a second messenger known to be involved in the regulation of cellular processes that might account for hepatic cyst formation. Several reports suggest that there is a direct correlation between cholangiocyte mass and cAMP levels; in vitro and in vivo, cholangiocyte proliferation is associated with an increase in cAMP concentrations, while a reduction in cholangiocyte mass is associated with decreased cAMP levels. 16 -18 Moreover, secretin, the major cAMP agonist in cholangiocytes, stimulates the targeting and insertion of several transporters and channels into the apical membrane of cholangiocytes and thereby facilitates fluid secretion. 19, 20 Indeed, in patients with ADPKD, intravenous administration of secretin enhances fluid secretion into the lumen of hepatic cysts. 21 Finally, cAMP plays a significant role in kidney cyst growth 22, 23 and reduction of cAMP levels in vivo attenuates renal disease progression. 24 Together, these data suggest that increased cAMP concentration may contribute to both hepatic and renal cystogenesis and that this pathway may provide a useful therapeutic target for PCLDs. Nevertheless, no data exist on the levels of cAMP in cholangiocytes in any of the PCLDs.
Somatostatin and its analogues, such as octreotide, have been shown to inhibit elevated cAMP levels and to decrease fluid secretion and cell proliferation in many cell types, including cholangiocytes. 16, [25] [26] [27] [28] Moreover, octreotide suppresses growth of both bile ducts and periportal connective tissue in rats with extrahepatic biliary obstruction. 29, 30 Interestingly, in a small number of patients with ADPKD, 6 months of octreotide long-acting release octreotideLAR therapy inhibited renal cyst growth. However, the role of drug in the progression of liver cystic disease was not evaluated in this study. 31 Furthermore, nothing is known regarding the effect of somatostatin on hepatic cystogenesis in any of the PCLDs.
To test whether the somatostatin analogue octreotide might be effective in the treatment of PCLDs, we chose the polycystic kidney (PCK) rat. In these rats, the spontaneous splicing mutation (IVS35-S2S¡T) of the Pkhd1 gene, which is orthologous to the human PKHD1, causes progressive hepatic and renal cyst formation. 11 We recently reported the liver pathology in the PCK rat, noting in particular that (1) liver cysts originate from the intrahepatic bile ducts and (2) cholangiocytes lining cysts have a disease-specific phenotype characterized by short and malformed cilia that do not express the Pkhd1 protein fibrocystin. 32, 33 In the present study, we assessed the effects of octreotide treatment on cAMP levels and the rate of cyst growth and expansion in isolated PCK bile ducts in vitro. Subsequently, we evaluated the time-dependent (4 -16 weeks) and dose-dependent (10 g and 100 g per kg body wt) effects of octreotide treatment on cAMP levels, hepatic and renal cyst formation, and fibrotic mass in vivo.
Materials and Methods

Animals and Diets
Wild-type Sprague-Dawley (n ϭ 15) and PCK (n ϭ 15 for in vitro study and n ϭ 60 for in vivo study) rats were maintained on a standard laboratory diet after approval by the Mayo Institutional Animal Care and Use Committee. Animals were anesthetized with pentobarbital (50 mg/kg body wt intraperitoneally). Blood samples were collected by cardiac puncture for evaluation of serum biochemistry and cAMP levels. Liver and kidneys were harvested, fixed in 10% formaldehyde, and embedded in paraffin for histologic analysis.
Octreotide Treatment Protocol
Three-week-old PCK rats were divided into 5 groups. Each group consisted of 2 subgroups: saline treated and octreotide treated (3 animals per treatment subgroup and gender). Octreotide (Novartis Pharma Stein AG, Basel, Switzerland) or saline dosages were adjusted to the animal weight twice a week. Groups 1, 2, 3, and 4 were treated for 4, 8, 12, and 16 weeks, respectively, with 10 g/kg body wt of octreotide. Group 5 received a higher dose of octreotide (100 g/kg body wt) for 4 weeks. All control groups received an equal volume of saline. Injections were given intraperitoneally twice a day, every day, at 12-hour intervals. At the end of each treatment period, 12 rats were killed and the following parameters were assessed: (1) body weight, (2) serum biochemistry, (3) liver and kidney weights, (4) cAMP levels in bile ducts and serum, (5) cystic volumes in liver and kidneys, and (6) hepatic and renal fibrosis. Both male and female rats were used in this study because gender differences affect phenotype in some forms of human PCLDs. 1 
Isolated Bile Ducts and 3-Dimensional Culture
Bile ducts were isolated as previously described. 34 For in vitro study, bile ducts were preincubated with (1) octreotide (10 Ϫ6 mol/L; Sigma Chemical Co, St Louis, MO), (2) 10 Ϫ7 mol/L of forskolin (Sigma Chemical Co) for 15 minutes, and (3) initially with 10 Ϫ7 mol/L of forskolin (15 minutes) and then, for an additional 15 minutes, with 10 Ϫ6 mol/L of octreotide. For 3-dimensional (3-D) culture, bile ducts were kept between 2 layers of type I rat tail collagen (1.5 mg/mL; BD Biosciences, San Jose, CA) plus 10% Matrigel (BD Biosciences) for 5 days. Octreotide (10 Ϫ6 mol/L) was added twice a day, daily, at 12-hour intervals. To study the role of cAMP in cyst progression, bile ducts were treated with octreotide (10 Ϫ6 mol/L) for 3 days and then with 10 Ϫ7 mol/L of forskolin for an additional 3 days. Development of cystic structures was assessed by light microscopy from days 1 to 6. The circumferential area of each cyst was measured using Image J software (National Institutes of Health).
cAMP Levels
The cAMP levels were measured in freshly isolated and 3-D-cultured bile ducts and in serum. Cultured bile ducts were first released from the gel by adding 0.4 mL of high-activity type XI collagenase (Sigma Chemical Co) for 45 minutes at 37°C and washing in media twice. cAMP concentrations were determined by the Bridge-It cAMP designer cAMP assay (Mediomics, LLC, St Louis, MO). Results were expressed in picomole per milligram DNA (for bile ducts) or picomole per milliliter (for serum). The amount of DNA in bile ducts was determined by using the DNeasy Tissue Kit (Qiagen Inc, Valencia, CA).
Scanning Electron Microscopy
Liver first was perfused with 4% paraformaldehyde ϩ 2% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.4) for 5-10 minutes, cut into small pieces (2-4 mm 3 ), and immersed in 2% phosphate-buffered glutaraldehyde for an additional 2 hours. Samples were postfixed in 1% osmium tetroxide for 1 hour, rinsed in distilled water, dehydrated in serial ethanol, dried in a critical point dryer, sputter coated with gold-palladium, and examined using a Hitachi 4700 scanning electron microscope (Hitachi Inc, Pleasanton, CA). Scanning electron micrographs were used to measure the length of cilia (Image J software).
RNA Isolation and Reverse-Transcription Polymerase Chain Reaction
RNA was isolated from microdissected bile ducts using TRIzol reagent (Invitrogen, Carlsbad, CA). Somatostatin receptor (SSTR) 2, SSTR3, and SSTR5 messenger RNA was detected by reverse transcription of the RNA to obtain complementary DNA, followed by polymerase chain reaction using the SuperScript III kit (Invitrogen). The following primers, corresponding to 5= and 3= regions of the SSTR2 (forward, TTCCAGAATGT-TCTTTTGCTTGG; reverse, TGTCCACCTATACTA-GACGC), SSTR3 (forward, GGAGGGAGAAGAGAA-CAGAAC; reverse, TGGGAATAGAGGATGGGAGG), and SSTR5 (forward, TCATTGTCAAC-ATCGTCAACC; reverse, TCCGAGAGAAAGCCGTAGAG), were designed and synthesized by Mayo Core Facility. Reverse-transcription polymerase chain reaction amplification was performed for 35 cycles. Each cycle consisted of denaturation at 94°C for 5 minutes, annealing at 50°C for 1 minute, and extension at 72°C for 7 minutes.
Immunohistochemistry and Immunofluorescence
Paraffin sections (5 m) of liver and kidneys were stained with H&E to measure cyst volume. Picrosirius red collagen stain was used to measure fibrosis. Hepatic and renal cystic and fibrosis volumes were detected using Meta-Morph software (Universal Imaging, West Chester, PA) installed on a Pentium IBM-compatible computer (Dell OptiPlex, Dell Ins, Round Rock, TX) following image acquisition using a light microscope and color digital camera (Nikon DXM 1200, Nikon Corporation, Kanagawa, Japan). The hepatic and renal cyst volume and fibrosis were expressed as a percentage of total liver or kidney parenchyma, respectively. We used SSTR2, SSTR3, and SSTR5 antibodies (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) to examine protein expression, proliferating cell nuclear antigen (PCNA) antibodies (Santa Cruz Biotechnology, Inc) to assess cell proliferation, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon International, Inc, Temecula, CA) to detect apoptosis. For mitotic and apoptotic indices, 1000 nuclei of cholangiocytes and renal tubular cells in randomly selected fields of liver and kidney sections were counted. The mitotic and apoptotic indices were calculated as a percentage of PCNA or terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-positive cells.
Statistics
All values are expressed as mean Ϯ SE. Statistical analysis was performed by the Student t test, and results were considered statistically different at P Ͻ .05.
Results
cAMP Levels Are Increased in the PCK Rat
We analyzed cAMP levels in freshly isolated bile ducts and serum of PCK rats and compared these levels with those of normal rats. cAMP concentrations in bile ducts of the PCK rat were significantly higher than in normal rats (7.19 Ϯ 1.42 vs 2.79 Ϯ 0.74 pmol/g DNA; P Ͻ .05). cAMP content was also significantly increased in the serum of PCK rats compared with normal rats (0.32 Ϯ 0.02 vs 0.19 Ϯ 0.04 pmol/mL; P Ͻ .05).
Octreotide Suppresses Elevated cAMP Levels In Vitro
Octreotide is known to inhibit accumulation of cAMP, decrease cell proliferation, and induce apoptosis by binding to several SSTRs (ie, SSTR2, SSTR3, and SSTR5). 25, 35, 36 Thus, we examined the expression of these 3 SSTRs in cholangiocytes of normal and PCK rats and found that they were all expressed at the message and protein levels in normal and cystic cholangiocytes (Figure 1 ).
To test whether octreotide alters cAMP concentration, we used freshly isolated bile ducts from normal and PCK rats. Addition of the drug did not affect the basal level of cAMP in normal rats (Figure 2A ). In contrast, in bile ducts isolated from the PCK rats, cAMP levels were inhibited by 43% in response to octreotide (P Ͻ .05; Figure 2A ). The observed effect of octreotide on cAMP content is consistent with the notion that in some cell types, somatostatin can decrease the level of this second messenger if it were previously activated. 25, 37, 38 Experimentally, the cAMP concentration in many types of cells can be increased by diterpene forskolin, a compound that stimulates cAMP production by activation of adenylyl cyclases via binding to their catalytic sites. 25, 37, 38 Indeed, pretreatment of both normal and PCK bile ducts with forskolin resulted in elevations of cAMP levels by 4.7-fold and 2.5-fold, respectively ( Figure 2B ). Octreotide inhibited forskolin-stimulated cAMP production in normal bile ducts by 53% and in PCK bile ducts by 39%, similar to the effects of somatostatin on forskolin-stimulated cAMP levels in other cell types. 25 These data suggest that cAMP levels are markedly increased in the PCK rat compared with normal rats and that octreotide can suppress elevated cAMP content.
Normal and PCK Bile Ducts Developed Cystic Structures in 3-D Culture
To further investigate the effect of octreotide on cyst expansion, a 3-D culture system was used. Under these conditions, both normal and PCK bile ducts develop cystic structures that progressively expand over time ( Figure 3A) . However, PCK bile ducts grow more rapidly; they expanded 2.6-fold by day 5 compared with a 1.7-fold increase in size in normal bile ducts ( Figure 3A and B). Moreover, in 3-D culture, cystic structures formed by normal and PCK bile ducts retained their in vivo morphology. In particular, cilia in PCK cystic structures were heterogeneous in length (range from 0.86 to 10.42 m) and significantly shorter (3.45 Ϯ 0.25 m; n ϭ 192; P Ͻ .001) than in cystic structures derived from normal bile ducts (6.97 Ϯ 0.59 m; n ϭ 110; Figure 3C ), consistent with what we have observed in the PCK rat in vivo. 32, 33 
Effect of Octreotide on Cyst Expansion In Vitro
Next, we analyzed the effect of octreotide on cAMP levels and circumferential areas of the cystic structures formed by bile duct in 3-D culture. In the absence of octreotide, cystic structures derived from PCK bile ducts progressively enlarged, exhibiting a 2.5-fold increase in size by day 5 as assessed by light microscopy ( Figure 4A ) and quantitation analysis ( Figure 4C ). Addition of octreotide to culture media resulted in inhibition of cAMP levels in cholangiocytes by up to 35% by day 5 ( Figure 4B ). Moreover, in octreotide-treated bile ducts, expansion of cystic structures was halted ( Figure 4A and C) . The similar effect of drug on cAMP levels and cystic circumferential areas was observed in normal rats (data not shown). Thus, our in vitro data suggest that octreotide treatment significantly inhibits cAMP concentrations and blocks hepatic cyst expansion.
Role of cAMP in Liver Cyst Progression
To further assess whether cAMP plays a significant role in liver cyst expansion, we performed the fol- lowing experiment. Bile ducts of the PCK rat grown in 3-D culture were treated with octreotide for 3 days. Octreotide prevented progressive cyst expansion by decreasing circumferential areas up to 27.8% ( Figure 5A and B) and cAMP levels up to 30.2% ( Figure 5C ). Three days later, octreotide was withdrawn from the culture media and supplemented with forskolin to stimulate production of cAMP. Addition of forskolin led to expansion of bile ducts by 16.7% ( Figure 5A and B) and elevation in cAMP levels by 22.4% ( Figure 5C ). Importantly, by day 6, the circumferential areas of cystic structures and cAMP levels were significantly less compared with day 1, suggesting that octreotide had a beneficial effect on hepatic cyst growth even after stopping octreotide treatment.
Octreotide Inhibits Hepatic and Renal Disease Progression In Vivo
Based on the results obtained in our in vitro study, we tested the time-and dose-dependent effects of octreotide on hepatic cyst progression and fibrosis in vivo in PCK rats (see Materials and Methods for details). Because 2 forms of PCLD, ADPKD and ARPKD, are associated with polycystic kidneys, we also examined renal cyst progression and fibrosis after octreotide treatment.
The following parameters were analyzed in both male and female PCK rats: body, liver, and kidney weight; biochemistry of serum, hepatic, and renal cyst volume; and hepatic and renal fibrosis. Octreotide had no effect on body weight and hepatic and renal function test (Supplementary Table 1 ; see supplemental material online at www.gastrojournal.org). In male and female PCK rats, octreotide treatment significantly lowered cAMP levels in bile ducts and serum in a time-dependent fashion and inhibited hepatic disease progression as reflected by a reduction in (1) liver weights up to 22%, (2) hepatic cyst volume up to 39%, and (3) hepatic fibrosis up to 44% (Figure 6 ). Similar effects were observed in kidneys of the PCK rats. In response to octreotide treatment, kidney weight was decreased by 19%, renal cystic volume by 39%, and renal fibrosis by 35% (Figure 7) . Furthermore, octreotide had a time-and dose-dependent effect on all (C) Scanning electron microscopy shows that cysts derived from bile ducts of normal and PCK rats retain their in vivo morphology. In particular, cilia in the PCK cystic structures were ϳ2 times shorter than in normal cystic structures. Bars ϭ 100 m (left panels), 10 m (middle panels), and 1 m (right panels). *P Ͻ .001 as compared with normal bile ducts. measured parameters in both organs; longer treatment and higher doses resulted in a more significant suppression of cAMP levels, which was accompanied by a more marked reduction in liver and kidney weights, hepatic and renal cyst volume, and fibrosis (Figures 6  and 7) .
Octreotide Decreases the Rate of Cell Proliferation in Hepatic and Renal Epithelia In Vivo
The effects of octreotide on cell proliferation were evaluated by analyzing the expression of PCNA, a protein involved in DNA replication. By the end of octreotide treatment, the number of PCNA-positive nuclei was decreased up to 60% in cholangiocytes and up to 49% in renal epithelial cells compared with saline-treated PCK rats (Figure 8) . Furthermore, the effect of octreotide on the rate of cell proliferation was time and dose dependent; longer treatment and higher dose led to a more substantial reduction in the percentage of PCNA-positive nuclei in liver and kidney. We also examined whether octreotide affects apoptosis in hepatic and renal epithelia and did not see any significant differences in percent of apoptotic cells between octreotide-and saline-treated PCK rats.
Discussion
This is the first study showing inhibition of hepatic cystogenesis in a rodent model orthologous to any of the human PCLDs. The results reported here show that (1) cAMP levels are markedly elevated in bile ducts and serum of the PCK rat compared with normal rats; (2) in vitro, octreotide lowers cAMP levels and halts cyst expansion; (3) in vivo, octreotide suppresses cAMP levels, reduces liver and kidney weights, inhibits hepatic and renal cyst volume and fibrosis, and decreases mitotic indices in hepatic and renal epithelia; and (4) in vivo, octreotide has time-and dose-dependent effects on the measured parameters, because longer treatment and higher dose lead to more substantial effects. In the presence of octreotide, cAMP levels were significantly lower. Note that cAMP levels in bile ducts growing in 3-D culture were higher than in freshly isolated bile ducts, reflecting the presence of forskolin in culture media. (C) Quantitative assessment of circumferential areas of cystic structures showed that octreotide treatment halted cyst expansion. *P Ͻ 05.
BASIC-LIVER,
PANCREAS, AND BILIARY TRACT
PCLD is a devastating disease; there are currently no effective preventive or curative treatments. In all, the PCLD gene mutations result in formation of multiple liver cysts that continue to expand during disease progression due to many different factors. 1, 3, 15, 39 One of these factors, cAMP, has been shown to play a significant role in 2 major processes that control cyst expansion: cell proliferation and fluid secretion. Indeed, our study shows for the first time that cAMP levels are increased in freshly isolated bile ducts and in serum of the PCK rats, an animal model of ARPKD (one form of the PCLDs). Moreover, we showed by in vitro and in vivo studies that suppression of cAMP content in cholangiocytes and serum halts cyst expansion. Thus, our data support the potential importance of this second messenger in hepatic disease progression and make cAMP an attractive therapeutic target in the treatment of PCLDs. Why cAMP levels are increased in cholangiocytes and serum of the PCK rat is now under investigation in our laboratory. We speculate that elevation of cAMP levels might reflect variable expression of the major components of the cAMP signaling cascade that all contribute to cAMP production, in particular, (1) increased expression of secretin receptors (because secretin is the major agonist of cAMP second messenger pathway in cholangiocytes), (2) decreased expression of SSTRs (because they are known to suppress cAMP levels), (3) variable expression of different adenylyl cyclases (because they are necessary for cAMP production), and (4) decreased expression of phosphodiesterases (because they participate in cAMP degradation) may all lead to elevated cAMP concentrations observed in the PCK rat. Additional studies are under way to explore all of these possibilities.
Octreotide is a synthetic, metabolically stable somatostatin analogue that binds to SSTR2 and SSTR5 with high affinity and to SSTR3 with low affinity. 35, 36, 40 Importantly, our data suggest that all these SSTRs are expressed in cholangiocytes of normal liver and in cystic epithelia of the PCK rat. Because cholangiocyte proliferation is one of the major mechanisms involved in hepatic cyst growth and expansion and elevated cAMP level is linked to this process, we hypothesized that suppression of cAMP levels by somatostatin or somatostatin analogues might potentially inhibit progression of cystic disease.
The ability of octreotide to halt cyst expansion by decreasing cell proliferation is consistent with its antiproliferative effects described previously by in vitro and in vivo studies. Octreotide can directly inhibit cell proliferation by interacting with SSTRs, although the precise mechanisms are unclear. 25, 35, 41, 42 It has been suggested recently that somatostatin and its analogues decrease cell proliferation mainly via activation of SSTR2, leading to inhibition of cAMP production. 25, 40, 43, 44 Indeed, our data showed that SSTR2 is expressed in cystic cholangiocytes and octreotide was able to significantly lower cAMP concentrations in a time-and dose-dependent fashion. As a result of this suppression, hepatic and renal disease progression was reduced. Moreover, proliferation of cholangiocyte and renal epithelial cells in octreotide-treated PCK rats was significantly decreased. We also do not exclude the possibility that octreotide may influence cell proliferation via an indirect effect, resulting from the inhibition of secretion of growth-promoting hormones and growth factors that are known to stimulate cholangiocyte proliferation. 35 The antiproliferative effects of octreotide can also be a consequence of apoptosis. 25, 35, 41, 44 A number of studies have shown that somatostatin triggers apoptosis mainly through SSTR3. 35, 42 Several reports have described a dose-dependent effect of octreotide (which has a low affinity for SSTR3) on induction of apoptosis. 45 For example, in mice bearing neuroendocrine tumors, a 3-fold increase in apoptosis was detected after administration of 300 g of octreotide. 46 In the present study, we did not find any differences in the apoptotic indices in liver and kidney epithelia of PCK rats. A similar lack of effect on apoptosis was previously observed in patients with gastrointestinal tumors 45, 46 and with pituitary adenomas 47 that were treated with doses of somatostatin analogues comparable to those used in our study, raising the possibility that higher doses of octreotide might accelerate cholangiocyte apoptosis.
Octreotide has been successfully used for the treatment of a number of human diseases, such as carcinoid tumors, VIPomas, hepatocellular carcinoma, and pancreatic tumors. 36 Our in vitro and in vivo data show that octreotide can inhibit hepatic and renal cystogenesis and attenuate hepatic and renal fibrosis, suggesting that octreotide should be considered for the treatment of human polycystic liver and kidney disease. Importantly, in a small study of patients with ADPKD treated with oc- 
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treotide long-acting release to reduce renal cyst expansion, the drug was safe and well tolerated. 31 Thus, octreotide is an attractive candidate for the treatment of PCLDs.
Advances in understanding mechanisms underlying renal and hepatic cyst progression, identification of genes responsible for disease development, and availability of different animal models of polycystic liver and kidney diseases have facilitated the development of a number of therapeutic approaches. For example, suppression of cAMP levels by an antagonist of the vasopressin V2 receptor inhibits renal cystic disease but has no effect on cystic liver disease because vasopressin receptors are not expressed in cholangiocytes. 24, 48 Inhibition of epidermal growth factor receptor tyrosine kinase activity decreases renal cystogenesis in animal models of ARPKD 49, 50 and ADPKD. 51 Unfortunately, these specific models have no genetically homologous human counterpart. Furthermore, in an orthologous rat model of human ARPKD, the PCK rat, the epidermal growth factor receptor inhibitor EKB-569 worsened both liver and kidney disease. 52 Surprisingly, a novel tyrosine kinase antagonist, gefitinib, reduces intrahepatic bile duct dilatation in the PCK rat 53 but worsens kidney disease. 53 Recently, rapamycin via mTOR inhibition has been shown to reduce renal cystogenesis in animal models of ADPKD 54 and ARPKD and in human patients with ADPKD. 55 However, the effects of rapamycin on cystic liver disease were not evaluated. Thus, while substantial progress has been made regarding therapies of polycystic kidney disease, development of treatment options of the polycystic liver has received less attention. Our study is the first showing inhibition of hepatic and renal cystogenesis in a rodent model orthologous to human PCLD.
In conclusion, the present study provides the first evidence that octreotide can suppress hepatic cyst growth in a rat model of one of the PCLDs by lowering cholangiocyte and serum cAMP levels. Moreover, octreotide also has beneficiary effects on renal cystic disease, an important observation because 2 forms of PCLD, ADPKD and ARPKD, are associated with polycystic kidneys. Finally, we have shown that octreotide is also a potent inhibitor of hepatic and renal fibrosis. Thus, this preclinical study provides a strong rationale for assessing the potential value of octreotide in the treatment of polycystic liver and kidney diseases in humans. However, because we only assessed octreotide in an animal model of one form of PCLD (ie, ARPKD), the usefulness of octreotide to inhibit hepatic cyst progression remains to be proved in animal models of ADPKD and autosomal dominant PCLD (when available) and in randomized clinical trials in patients with PCLD. Importantly, a clinical trial that will evaluate the effect of octreotide long-acting release on liver cyst volumes in patients with severe PCLDs is now under way at our institution.
